Trial reportBlood2018
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Nature communications · 2021Pooled it
- The Causal Role of the Gut Microbiota-Plasma Metabolome Axis in Myeloproliferative Neoplasm Pathogenesis: A Mendelian Randomization and Mediation Analysis.Metabolites · 2025Article
- Evolution of myeloproliferative neoplasms from normal blood stem cells.Haematologica · 2025Review
- Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.British journal of haematology · 2024Review
- Article
- BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.Annals of hematology · 2024Article
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Cancers · 2024Review
- Characterization of myeloproliferative neoplasms in the paediatric and young adult population.British journal of haematology · 2023Article
- MYB insufficiency disrupts proteostasis in hematopoietic stem cells, leading to age-related neoplasia.Blood · 2023Article
- Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.Leukemia · 2023Article
- Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder.Frontiers in oncology · 2023Review
- The Contribution ofInternational journal of molecular sciences · 2022Review
- Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis.Nature communications · 2022Article
- CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.Cell death & disease · 2022Article
- Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms.EJHaem · 2022Article
- Case of Patient with AML with Complex Karyotype including Ultra-Rare t(4;8)(q32;q13), t(4;11)(q21;p15) and Familial Aggregation of Myeloid Malignancies.Medicina (Kaunas, Lithuania) · 2022Article
- Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.Leukemia · 2022Article
- Article
- Molecular pathogenesis of the myeloproliferative neoplasms.Journal of hematology & oncology · 2021Review
- GermlineCancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.